Literature DB >> 22857857

Prostate post-implant dosimetry: interobserver variability in seed localisation, contouring and fusion.

Marisol De Brabandere1, Peter Hoskin, Karin Haustermans, Frank Van den Heuvel, Frank-André Siebert.   

Abstract

AIM: Reliable post-implant evaluation of prostate seed implants requires optimal seed identification and accurate delineation of anatomical structures. In this study the GEC-ESTRO groups BRAPHYQS and PROBATE investigated the interobserver variability in post-implant prostate contouring, seed reconstruction and image fusion and its impact on the dose-volume parameters. MATERIALS: Post-implant T2-TSE, T1-GE and CT images were acquired for three patients, in order to evaluate four post-plan techniques: (a) CT, (b) T1+T2, (c) CT+T2, (d) CT+T1(int)+T2. Three interobserver studies were set up. (1) Contouring: the CTV-prostate was delineated on CT and T2 by eight physicians. Additionally one reference contour was defined on both image modalities for each patient. (2) Seed reconstruction: seven physicists localised the seeds on T1 and CT, manually and with CT seed finder tools. A reference seed geometry was defined on CT and T1. (3) Fusion: six physicists registered the image sets for technique (b)-(d), using seeds (if visible) and anatomical landmarks. A reference fusion was determined for each combined technique.
RESULTS: (1) The SD(ref) for contouring (1 SD with respect to the reference volume) was largest for CT (23%), but also surprisingly large for MRI (17%). This resulted in large SD(ref) values for D90 for all techniques (17-23%). The surprisingly large SD(ref) for MRI was partly due to variations in interpretation of what to include in the prostate contour. (2) The SD(ref) in D90 for seed reconstruction was small (2%) for all techniques, except for T1+T2 (7%). (3) The SD(ref) in D90 due to image fusion was quite large, especially for direct fusion of CT+T2 (16%) where clearly corresponding landmarks were missing (seeds hardly visible on T2). In general, we observed large differences in D90 depending on the technique used.
CONCLUSIONS: The dosimetric parameters for prostate post-implant evaluation showed large technique-dependent interobserver variabilities. Contouring and image fusion are the 'weak links' in the procedure. Guidelines and training in contouring together with incorporation of automated fusion software need to be implemented.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22857857     DOI: 10.1016/j.radonc.2012.06.014

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  14 in total

1.  Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers.

Authors:  Geoffrey V Martin; Thomas J Pugh; Usama Mahmood; Rajat J Kudchadker; Jihong Wang; Teresa L Bruno; Tharakeswara Bathala; Pierre Blanchard; Steven J Frank
Journal:  Brachytherapy       Date:  2017-05-10       Impact factor: 2.362

2.  Pulse sequence considerations for simulation and postimplant dosimetry of prostate brachytherapy.

Authors:  Jingfei Ma; Marinus A Moerland; Aradhana M Venkatesan; Tharakeswara K Bathala; Rajat J Kudchadker; Kristy K Brock; Steven J Frank
Journal:  Brachytherapy       Date:  2017-01-04       Impact factor: 2.362

3.  Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled.

Authors:  Kris T Huang; Radka Stoyanova; Gail Walker; Kiri Sandler; Matthew T Studenski; Nesrin Dogan; Tahseen Al-Saleem; Mark K Buyyounouski; Eric M Horwitz; Alan Pollack
Journal:  Radiother Oncol       Date:  2015-05-08       Impact factor: 6.280

4.  Prospective Evaluation of Prostate and Organs at Risk Segmentation Software for MRI-based Prostate Radiation Therapy.

Authors:  Jeremiah W Sanders; Rajat J Kudchadker; Chad Tang; Henry Mok; Aradhana M Venkatesan; Howard D Thames; Steven J Frank
Journal:  Radiol Artif Intell       Date:  2022-01-26

Review 5.  Magnetic resonance image guided brachytherapy.

Authors:  Kari Tanderup; Akila N Viswanathan; Christian Kirisits; Steven J Frank
Journal:  Semin Radiat Oncol       Date:  2014-07       Impact factor: 5.934

6.  Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy.

Authors:  Gilles Crehange; Devan Krishnamurthy; J Adam Cunha; Barby Pickett; John Kurhanewicz; I-Chow Hsu; Alexander R Gottschalk; Katsuto Shinohara; Mack Roach; Jean Pouliot
Journal:  Radiother Oncol       Date:  2013-11-11       Impact factor: 6.280

7.  Prognostic Value of Pretreatment MRI in Patients With Prostate Cancer Treated With Radiation Therapy: A Systematic Review and Meta-Analysis.

Authors:  Sungmin Woo; Sangwon Han; Tae-Hyung Kim; Chong Hyun Suh; Antonio C Westphalen; Hedvig Hricak; Michael J Zelefsky; Hebert Alberto Vargas
Journal:  AJR Am J Roentgenol       Date:  2019-12-04       Impact factor: 3.959

8.  Impact of dosimetric differences between CT and MRI derived target volumes for external beam cervical cancer radiotherapy.

Authors:  Vikneswary Batumalai; Siobhan Burke; Dale Roach; Karen Lim; Glen Dinsdale; Michael Jameson; Cesar Ochoa; Jacqueline Veera; Lois Holloway; Shalini Vinod
Journal:  Br J Radiol       Date:  2020-06-18       Impact factor: 3.039

9.  Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection.

Authors:  Carl Salembier; Alex Rijnders; Ann Henry; Peter Niehoff; Frank André Siebert; Peter Hoskin
Journal:  J Contemp Brachytherapy       Date:  2013-06-28

Review 10.  Review of clinical brachytherapy uncertainties: analysis guidelines of GEC-ESTRO and the AAPM.

Authors:  Christian Kirisits; Mark J Rivard; Dimos Baltas; Facundo Ballester; Marisol De Brabandere; Rob van der Laarse; Yury Niatsetski; Panagiotis Papagiannis; Taran Paulsen Hellebust; Jose Perez-Calatayud; Kari Tanderup; Jack L M Venselaar; Frank-André Siebert
Journal:  Radiother Oncol       Date:  2013-11-30       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.